Axsome Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of $0.57 Per Share (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) – Analysts at William Blair issued their Q1 2024 EPS estimates for shares of Axsome Therapeutics in a research report issued on Monday, May 2nd. William Blair analyst M. Minter expects that the company will post earnings of $0.57 per share for the quarter.

Axsome Therapeutics (NASDAQ:AXSMGet Rating) last announced its earnings results on Monday, May 2nd. The company reported ($1.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.00) by ($0.03). During the same period in the previous year, the business earned ($0.78) earnings per share.

A number of other brokerages have also recently issued reports on AXSM. SVB Leerink cut their target price on Axsome Therapeutics from $65.00 to $50.00 and set an “outperform” rating on the stock in a report on Wednesday, March 2nd. Zacks Investment Research cut Axsome Therapeutics from a “buy” rating to a “hold” rating and set a $32.00 target price on the stock. in a report on Friday, March 4th. StockNews.com began coverage on Axsome Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Mizuho cut their target price on Axsome Therapeutics from $51.00 to $49.00 in a report on Tuesday. Finally, Jefferies Financial Group increased their target price on Axsome Therapeutics from $71.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Axsome Therapeutics currently has an average rating of “Buy” and an average target price of $80.58.

Axsome Therapeutics stock opened at $35.84 on Wednesday. Axsome Therapeutics has a 52-week low of $19.38 and a 52-week high of $74.10. The stock’s 50 day moving average price is $35.19 and its two-hundred day moving average price is $34.48. The company has a debt-to-equity ratio of 3.14, a quick ratio of 3.75 and a current ratio of 3.75.

A number of institutional investors and hedge funds have recently made changes to their positions in AXSM. Atticus Wealth Management LLC bought a new position in Axsome Therapeutics in the 3rd quarter worth about $30,000. Tortoise Investment Management LLC bought a new position in Axsome Therapeutics in the 4th quarter worth about $49,000. Nisa Investment Advisors LLC boosted its stake in Axsome Therapeutics by 324.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,078 shares of the company’s stock worth $57,000 after purchasing an additional 1,588 shares during the period. Allspring Global Investments Holdings LLC bought a new position in Axsome Therapeutics in the 1st quarter worth about $141,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Axsome Therapeutics by 27.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,827 shares of the company’s stock worth $158,000 after purchasing an additional 831 shares during the period. 48.46% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile (Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Featured Stories

Earnings History and Estimates for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.